Entrada Therapeutics (TRDA): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
4 concentrated managers hold it (+1 vs last quarter) with a median weight of 0.2%. 1 officer or director bought in 6 months.
Who owns Entrada Therapeutics?
Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Kush Parmar, 10.8% (13D/A filed Nov 18, 2025), Ansbert Gadicke, 9.9% (13D/A filed Sep 10, 2026), Roche Finance, 6.9% (13G/A filed Feb 14, 2025) and BlackRock, 5.3% (13G filed Feb 4, 2025). Mpm Bioventures 2018 (B), L.P., MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 (B), L.P. are listed on their Form 4 filings as owners of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Baker Bros. Advisors (13.1% of the shares), 5AM Venture Management (10.4%) and BlackRock (6.7%).
Which institutions hold the most Entrada Therapeutics shares?
Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:
- 1. Baker Bros. Advisors: 13.1%
- 2. 5AM Venture Management: 10.4%
- 3. BlackRock: 6.7%
- 4. Merck: 4.5%
- 5. Vanguard Capital Management: 3.3%
- 6. MPM Bioimpact: 3.2%
- 7. TCG Crossover Management: 2.7%
- 8. Wellington Management Group LLP: 2.5%
- 9. Millennium Management: 2.0%
- 10. StepStone Group: 2.0%
How much of Entrada Therapeutics do institutions own?
The 128 institutions that file 13F reported 74.9% of the shares as of Jun 30, 2026.
Sources:13D/A by Kush Parmar (Nov 18, 2025) ↗13D/A by Ansbert Gadicke (Sep 10, 2026) ↗13G/A by Roche Finance (Feb 14, 2025) ↗13G by BlackRock (Feb 4, 2025) ↗All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Apr 30, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Entrada Therapeutics revenue
Entrada Therapeutics reported annual revenue of $25.4 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (3 → 4): 1 opened · 0 exited = +1
Net flow in the quarter: −$54K (−7 K shares) · bought $9.2M and sold $9.3MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Baker Bros. Advisors$37.3M0.2%
- MPM BioimpactNew$9.2M0.6%+0.6 pp
- TCG Crossover ManagementReduced$7.8M0.2%−0.2 pp
- Lynx1 Capital ManagementReduced$1.3M0.2%−0.0 pp
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of TRDA (all 13F filers)
- Baker Bros. Advisorsconcentrated5.1 MInvestment firm · 13.03% of the company0
- 5AM Venture Management4.1 MPrivate equity or venture capital · 10.42% of the company0
- BlackRock2.6 MIndex manager · 6.63% of the company+225 K
- Merck1.7 MOperating company · 4.47% of the company+1.7 M
- Vanguard Capital Management1.3 MIndex manager · 3.26% of the company+14 K
- MPM Bioimpactconcentrated1.3 MInvestment firm · 3.22% of the company+1.3 M
- TCG Crossover Managementconcentrated1.1 MInvestment firm · 2.72% of the company−1.2 M
- Wellington Management Group LLP954 KInvestment firm · 2.45% of the company−80 K
- Millennium Management764 KQuant or multi-manager · 1.96% of the company+245 K
- StepStone Group761 KType not verified · 1.96% of the company0
- Baker Bros. Advisorsconcentrated
- Shares
- 5.1 M
- Change
- 0
- % of the company
- 13.03%
See more
- Type
- Investment firm
- Value
- $37.3M
- Shares
- 4.1 M
- Change
- 0
- % of the company
- 10.42%
See more
- Type
- Private equity or venture capital
- Value
- $29.9M
- Shares
- 2.6 M
- Change
- +225 K
- % of the company
- 6.63%
See more
- Type
- Index manager
- Value
- $19.0M
- Merck
- Shares
- 1.7 M
- Change
- +1.7 M
- % of the company
- 4.47%
See more
- Type
- Operating company
- Value
- $12.8M
- Shares
- 1.3 M
- Change
- +14 K
- % of the company
- 3.26%
See more
- Type
- Index manager
- Value
- $9.3M
- MPM Bioimpactconcentrated
- Shares
- 1.3 M
- Change
- +1.3 M
- % of the company
- 3.22%
See more
- Type
- Investment firm
- Value
- $9.2M
- TCG Crossover Managementconcentrated
- Shares
- 1.1 M
- Change
- −1.2 M
- % of the company
- 2.72%
See more
- Type
- Investment firm
- Value
- $7.8M
- Shares
- 954 K
- Change
- −80 K
- % of the company
- 2.45%
See more
- Type
- Investment firm
- Value
- $7.0M
- Shares
- 764 K
- Change
- +245 K
- % of the company
- 1.96%
See more
- Type
- Quant or multi-manager
- Value
- $5.6M
- Shares
- 761 K
- Change
- 0
- % of the company
- 1.96%
See more
- Type
- Type not verified
- Value
- $5.6M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 74.9% of the shares · top 10: 50.3% · in index firms: 22.5% of the institutional total
Q2 2026: 74.9%
Shares reported by the 128 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Apr 30, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- -71.0%
- Revenue (TTM)
- $4.7M
- Revenue growth
- -94.1%
- Net income (TTM)
- $-166M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-134M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 41.4 M
There is a jump that may be an undetected split: we do not show the changes.
- Buybacks (FY 2025)
- no data
- Share issuance
- no data
- Stock-based compensation
- $19.6M77.1% of revenue
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- no data
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers